These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29941343)

  • 1. Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
    Yang Z; Zhang R; Ge Y; Qin X; Kang X; Wang Y; Zhang X; Song C; Quan X; Wang H; Chen H; Li C
    EBioMedicine; 2018 Sep; 35():198-203. PubMed ID: 29941343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
    Groenendijk FH; de Jong J; Fransen van de Putte EE; Michaut M; Schlicker A; Peters D; Velds A; Nieuwland M; van den Heuvel MM; Kerkhoven RM; Wessels LF; Broeks A; van Rhijn BW; Bernards R; van der Heijden MS
    Eur Urol; 2016 Mar; 69(3):384-8. PubMed ID: 25636205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
    Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
    Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
    Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
    Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
    Kompier LC; Lurkin I; van der Aa MN; van Rhijn BW; van der Kwast TH; Zwarthoff EC
    PLoS One; 2010 Nov; 5(11):e13821. PubMed ID: 21072204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment.
    Ecke TH; Voß PC; Schlomm T; Rabien A; Friedersdorff F; Barski D; Otto T; Waldner M; Veltrup E; Linden F; Hake R; Eidt S; Roggisch J; Heidenreich A; Rieger C; Kastner L; Hallmann S; Koch S; Wirtz RM
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?
    van Rhijn BWG; Mertens LS; Mayr R; Bostrom PJ; Real FX; Zwarthoff EC; Boormans JL; Abas C; van Leenders GJLH; Götz S; Hippe K; Bertz S; Neuzillet Y; Sanders J; Broeks A; van der Heijden MS; Jewett MAS; Marquez M; Stoehr R; Zlotta AR; Eckstein M; Soorojebally Y; Roshani H; Burger M; Otto W; Radvanyi F; Sirab N; Pouessel D; Wullich B; van der Kwast TH; Malats N; Hartmann A; Allory Y; Zuiverloon TCM
    Eur Urol; 2020 Nov; 78(5):682-687. PubMed ID: 32682615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
    Pouessel D; Neuzillet Y; Mertens LS; van der Heijden MS; de Jong J; Sanders J; Peters D; Leroy K; Manceau A; Maille P; Soyeux P; Moktefi A; Semprez F; Vordos D; de la Taille A; Hurst CD; Tomlinson DC; Harnden P; Bostrom PJ; Mirtti T; Horenblas S; Loriot Y; Houédé N; Chevreau C; Beuzeboc P; Shariat SF; Sagalowsky AI; Ashfaq R; Burger M; Jewett MA; Zlotta AR; Broeks A; Bapat B; Knowles MA; Lotan Y; van der Kwast TH; Culine S; Allory Y; van Rhijn BW
    Ann Oncol; 2016 Jul; 27(7):1311-6. PubMed ID: 27091807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.
    Le Goux C; Vacher S; Schnitzler A; Barry Delongchamps N; Zerbib M; Peyromaure M; Sibony M; Allory Y; Bieche I; Damotte D; Pignot G
    Sci Rep; 2020 Oct; 10(1):16641. PubMed ID: 33024200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.
    Mertens LS; Claps F; Mayr R; Bostrom PJ; Shariat SF; Zwarthoff EC; Boormans JL; Abas C; van Leenders GJLH; Götz S; Hippe K; Bertz S; Neuzillet Y; Sanders J; Broeks A; Peters D; van der Heijden MS; Jewett MAS; Stöhr R; Zlotta AR; Eckstein M; Soorojebally Y; van der Schoot DKE; Wullich B; Burger M; Otto W; Radvanyi F; Sirab N; Pouessel D; van der Kwast TH; Hartmann A; Lotan Y; Allory Y; Zuiverloon TCM; van Rhijn BWG
    Urol Oncol; 2022 Mar; 40(3):110.e1-110.e9. PubMed ID: 34906411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study.
    Necchi A; Raggi D; Giannatempo P; Marandino L; Farè E; Gallina A; Colecchia M; Lucianò R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Dittamore R; Liu Y; Davicioni E; Ross JS; de Jong JJ; Briganti A; Montorsi F; Gibb EA
    Eur Urol Oncol; 2021 Dec; 4(6):1001-1005. PubMed ID: 32417369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.
    Gil-Jimenez A; van Dorp J; Contreras-Sanz A; van der Vos K; Vis DJ; Braaf L; Broeks A; Kerkhoven R; van Kessel KEM; Ribal MJ; Alcaraz A; Wessels LFA; Seiler R; Wright JL; Mengual L; Boormans J; van Rhijn BWG; Black PC; van der Heijden MS
    Eur Urol; 2023 Apr; 83(4):313-317. PubMed ID: 35965206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.
    Smal MP; Rolevich AI; Polyakov SL; Krasny SA; Goncharova RI
    Exp Oncol; 2014 Dec; 36(4):246-51. PubMed ID: 25537218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder cancer: novel molecular characteristics, diagnostic, and therapeutic implications.
    Kompier LC; van Tilborg AA; Zwarthoff EC
    Urol Oncol; 2010; 28(1):91-6. PubMed ID: 20123356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
    Kim YS; Kim K; Kwon GY; Lee SJ; Park SH
    BMC Urol; 2018 Jul; 18(1):68. PubMed ID: 30064409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
    Choi W; Porten S; Kim S; Willis D; Plimack ER; Hoffman-Censits J; Roth B; Cheng T; Tran M; Lee IL; Melquist J; Bondaruk J; Majewski T; Zhang S; Pretzsch S; Baggerly K; Siefker-Radtke A; Czerniak B; Dinney CP; McConkey DJ
    Cancer Cell; 2014 Feb; 25(2):152-65. PubMed ID: 24525232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.